Convulsive status epilepticus should be initially managed with IV lorazepam, with a repeat dose given 10 minutes later if the seizure persists or recurs. Buccal midazolam may be used if IV access is not available or if the seizure occurs outside of a hospital setting. It is important to note that a maximum of two doses of IV benzodiazepines should be administered during convulsive status epilepticus. Intravenous carbamazepine is not appropriate for acute seizure management, as it is primarily used for preventing tonic-clonic seizures. Intravenous phenytoin should not be given until two doses of benzodiazepines have been administered, and at this point, critical care and anesthesia should also be involved. Rectal diazepam is typically not used unless there is no IV access or the emergency occurs outside of a hospital setting.

Status epilepticus is a medical emergency that occurs when a person experiences a single seizure lasting more than five minutes or two seizures within a five-minute period without returning to normal between them. It is crucial to terminate seizure activity as soon as possible to prevent irreversible brain damage. The first step in managing status epilepticus is to ensure the patient’s airway is clear and provide oxygen while checking their blood glucose levels. The first-line treatment is IV benzodiazepines, such as diazepam or lorazepam, with PR diazepam or buccal midazolam given in the prehospital setting. In the hospital, IV lorazepam is typically used and may be repeated once after 10-20 minutes. If the status epilepticus persists, a second-line agent such as phenytoin or phenobarbital infusion may be administered. If there is no response within 45 minutes, induction of general anesthesia is the best way to achieve rapid control of seizure activity.

Breastfeeding has some contraindications that are important to know, especially when it comes to drugs. Antibiotics like penicillins, cephalosporins, and trimethoprim are safe for breastfeeding mothers, as are endocrine drugs like glucocorticoids (in low doses) and levothyroxine. Epilepsy drugs like sodium valproate and carbamazepine, asthma drugs like salbutamol and theophyllines, and hypertension drugs like beta-blockers and hydralazine are also safe. Anticoagulants like warfarin and heparin, as well as digoxin, are also safe. However, some drugs should be avoided, such as antibiotics like ciprofloxacin, tetracycline, chloramphenicol, and sulphonamides, psychiatric drugs like lithium and benzodiazepines, aspirin, carbimazole, methotrexate, sulfonylureas, cytotoxic drugs, and amiodarone. Other contraindications include galactosaemia and viral infections, although the latter is controversial in the developing world due to the increased risk of infant mortality and morbidity associated with bottle feeding.

Acute viral labyrinthitis presents with sudden horizontal nystagmus, hearing issues, nausea, vomiting, and vertigo. It is typically preceded by a viral infection and can cause hearing loss. Unlike BPPV, it is not associated with hearing loss. A central cause such as a stroke is less likely as the nystagmus is unidirectional and the head impulse test is impaired. Vestibular neuritis has similar symptoms to viral labyrinthitis but does not result in hearing loss.

Labyrinthitis is a condition that involves inflammation of the membranous labyrinth, which affects both the vestibular and cochlear end organs. This disorder can be caused by a viral, bacterial, or systemic disease, with viral labyrinthitis being the most common form. It is important to distinguish labyrinthitis from vestibular neuritis, as the latter only affects the vestibular nerve and does not result in hearing impairment. Labyrinthitis, on the other hand, affects both the vestibular nerve and the labyrinth, leading to vertigo and hearing loss.

The typical age range for presentation of labyrinthitis is between 40-70 years old. Patients usually experience an acute onset of symptoms, including vertigo that is not triggered by movement but worsened by it, nausea and vomiting, hearing loss (which can be unilateral or bilateral), tinnitus, and preceding or concurrent upper respiratory tract infection symptoms. Signs of labyrinthitis include spontaneous unidirectional horizontal nystagmus towards the unaffected side, sensorineural hearing loss, an abnormal head impulse test, and gait disturbance that may cause the patient to fall towards the affected side.

Diagnosis of labyrinthitis is primarily based on the patient’s history and physical examination. While episodes of labyrinthitis are typically self-limiting, medications such as prochlorperazine or antihistamines may help reduce the sensation of dizziness. Overall, it is important to accurately diagnose and manage labyrinthitis to prevent complications and improve the patient’s quality of life.

Chickenpox exposure in pregnancy can pose risks to both the mother and fetus, including fetal varicella syndrome. Post-exposure prophylaxis (PEP) with varicella-zoster immunoglobulin (VZIG) or antivirals should be given to non-immune pregnant women, with timing dependent on gestational age. If a pregnant woman develops chickenpox, specialist advice should be sought and oral aciclovir may be given if she is ≥ 20 weeks and presents within 24 hours of onset of the rash.

The patient should be advised to avoid deep-sea diving for life due to the risk of pneumothorax. However, they can fly one week after having a chest x-ray showing complete resolution of the pneumothorax. There is no increased risk of catamenial pneumothoraces. Pleurodesis is not necessary for a single pneumothorax, whether primary or secondary.

Management of Pneumothorax: BTS Guidelines

Pneumothorax is a condition where air accumulates in the pleural space, causing the lung to collapse. The British Thoracic Society (BTS) has published updated guidelines for the management of spontaneous pneumothorax, which can be primary or secondary. Primary pneumothorax occurs without any underlying lung disease, while secondary pneumothorax is associated with lung disease.

The BTS guidelines recommend that patients with a rim of air less than 2cm and no shortness of breath may be discharged, while those with a larger rim of air or shortness of breath should undergo aspiration or chest drain insertion. For secondary pneumothorax, patients over 50 years old with a rim of air greater than 2cm or shortness of breath should undergo chest drain insertion. Aspiration may be attempted for those with a rim of air between 1-2cm, but chest drain insertion is necessary if aspiration fails.

For iatrogenic pneumothorax, observation is usually sufficient, but chest drain insertion may be necessary in some cases. Ventilated patients and those with chronic obstructive pulmonary disease (COPD) may require chest drain insertion. If a patient has persistent or recurrent pneumothorax, video-assisted thoracoscopic surgery (VATS) may be necessary.

Patients should be advised to avoid smoking to reduce the risk of further episodes. Fitness to fly is an absolute contraindication, but patients may travel 1 week after successful drainage if there is no residual air. Scuba diving should be permanently avoided unless the patient has undergone bilateral surgical pleurectomy and has normal lung function and chest CT scan postoperatively.

Overall, the BTS guidelines provide a comprehensive approach to the management of pneumothorax, taking into account the type of pneumothorax, patient characteristics, and potential complications.

Men with BRCA2 mutation are at a higher risk of developing prostate cancer, while both men and women with this mutation have a significantly increased risk of developing breast cancer. Additionally, women with BRCA2 mutation are more likely to develop ovarian cancer. Although young-onset colorectal cancer is linked to BRCA1 mutation, there is no such association observed in individuals with BRCA2 mutation.

Li-Fraumeni Syndrome is caused by mutations in the p53 gene and increases the risk of developing sarcomas and leukemias. BRCA 1 and 2 mutations increase the risk of breast and ovarian cancer, and BRCA 2 is also associated with prostate cancer in men. Lynch Syndrome increases the risk of colon and endometrial cancer, and can be identified using the Amsterdam criteria. Gardner’s Syndrome is a familial colorectal polyposis that can lead to colectomy to reduce the risk of colorectal cancer.

Understanding Radiation Enteritis and Other Possible Causes of Bowel Symptoms

Radiation enteritis is a condition that occurs when the bowel becomes inflamed due to radiation therapy. It can manifest as ileitis, colitis, or proctitis, and can be acute or chronic. Acute radiation enteritis typically occurs during therapy and presents with symptoms such as anorexia, diarrhoea, and abdominal pain. Chronic radiation enteritis, on the other hand, can develop months or years after treatment and may cause weight loss, steatorrhoea, and small bowel obstruction.

While radiation enteritis is a likely cause of bowel symptoms in patients who have undergone radiation therapy, other conditions should also be considered. Bowel obstruction, for example, can cause nausea, vomiting, and bloating, but does not typically cause diarrhoea. Local malignant infiltration to the bowel may present with obstruction, while bowel perforation is a medical emergency that causes peritonitis and sepsis.

In summary, understanding the possible causes of bowel symptoms is important in determining the appropriate treatment for patients. While radiation enteritis is a common consequence of radiation therapy, other conditions such as bowel obstruction, local malignant infiltration, and bowel perforation should also be considered.

If the woman does not approve of hormonal treatments, alternatives such as tranexamic acid or NSAIDs can be utilized according to NICE CG44.

Managing Heavy Menstrual Bleeding

Heavy menstrual bleeding, also known as menorrhagia, is a condition where a woman experiences excessive blood loss during her menstrual cycle. While it was previously defined as total blood loss of over 80 ml per cycle, the management of menorrhagia now depends on the woman’s perception of what is excessive. In the past, hysterectomy was a common treatment for heavy periods, but the approach has changed significantly since the 1990s.

To manage menorrhagia, a full blood count should be performed in all women. If symptoms suggest a structural or histological abnormality, a routine transvaginal ultrasound scan should be arranged. For women who do not require contraception, mefenamic acid or tranexamic acid can be used. If there is no improvement, other drugs can be tried while awaiting referral.

For women who require contraception, options include the intrauterine system (Mirena), combined oral contraceptive pill, and long-acting progestogens. Norethisterone can also be used as a short-term option to rapidly stop heavy menstrual bleeding. The flowchart below shows the management of menorrhagia.

[Insert flowchart here]

Young athletes with hypertrophic obstructive cardiomyopathy are at risk of sudden death due to ventricular arrhythmia. This is believed to be caused by ventricular tachycardia resulting from ischaemia, which typically occurs during extreme exertion. Unlike myocardial infarction, which is commonly associated with atherosclerosis in the coronary arteries, it is unlikely for a young person to develop this condition. However, cocaine use may increase the risk of MI in young people. Although HOCM may cause a regurgitant mitral valve, valve rupture is not a known complication. While heart block may occur in some cases of HOCM, it is rare and is unlikely to cause sudden death.

Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic disorder that affects muscle tissue and is caused by mutations in genes encoding contractile proteins. It is characterized by left ventricle hypertrophy, diastolic dysfunction, and myofibrillar hypertrophy with disarray and fibrosis on biopsy. HOCM can be asymptomatic or present with exertional dyspnea, angina, syncope, sudden death, arrhythmias, heart failure, jerky pulse, and systolic murmurs. It is associated with Friedreich’s ataxia and Wolff-Parkinson White. ECG findings include left ventricular hypertrophy, non-specific ST segment and T-wave abnormalities, and deep Q waves.

Individuals who receive long-term treatment with an aminoglycoside may experience some level of ototoxicity. Fluoroquinolones, such as ciprofloxacin and levofloxacin, are not associated with ototoxicity but can interfere with connective tissue and increase the risk of tendon rupture. Glycopeptides, which include vancomycin, are more likely to cause nephrotoxicity than ototoxicity, although rare cases of ototoxicity have been reported at high serum concentrations. Macrolides, such as erythromycin, clarithromycin, and azithromycin, do not cause ototoxicity but may lead to myopathy or QT prolongation as significant adverse effects.

Gentamicin is a type of antibiotic belonging to the aminoglycoside class. It is not easily soluble in lipids, which is why it is administered either parentally or topically. Gentamicin is commonly used to treat infective endocarditis and otitis externa. However, it is important to note that gentamicin can cause adverse effects such as ototoxicity and nephrotoxicity. Ototoxicity is caused by damage to the auditory or vestibular nerve, which can be irreversible. Nephrotoxicity occurs when gentamicin accumulates in the body, particularly in patients with renal failure, leading to acute tubular necrosis. The risk of toxicity is increased when gentamicin is used in conjunction with furosemide. Therefore, lower doses and more frequent monitoring are required.

It is important to note that gentamicin is contraindicated in patients with myasthenia gravis. Due to the potential for toxicity, it is crucial to monitor plasma concentrations of gentamicin. Both peak levels (measured one hour after administration) and trough levels (measured just before the next dose) are monitored. If the trough level is high, the interval between doses should be increased. If the peak level is high, the dose should be decreased. By carefully monitoring gentamicin levels, healthcare providers can ensure that patients receive the appropriate dose without experiencing adverse effects.